Argenica Therapeutics Ltd ASX: AGN Share Price & Review

AGN Overview

AGN Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About AGN

Website

N/A

Telephone

61.8.9329.3396

Address

Unit 4, 117 Broadway Nedlands, Western Australia (WA) 6009

Description

Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.

AGN Price Chart

Key Stats

Market Cap

AU$82.85M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.6 - 0.88

Trade Value (12mth)

AU$22,269.00

1 week

0.78%

1 month

-3.73%

YTD

1.57%

1 year

-19.38%

All time high

1.02

Key Fundamentals

EPS 3 yr Growth

1.60%

EBITDA Margin

N/A

Operating Cashflow

-$6m

Free Cash Flow Return

-53.80%

ROIC

-67.70%

Interest Coverage

N/A

Quick Ratio

2.90

Other Data

Shares on Issue (Fully Dilluted)

128m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

AGN Announcements

Latest Announcements

Date	Announcements
01 September 25	Trading Halt × Trading Halt
28 August 25	Appendix 4E & Annual Report to 30 June 2025 × Appendix 4E & Annual Report to 30 June 2025
28 August 25	Appendix 4G & Corporate Governance Statement × Appendix 4G & Corporate Governance Statement
14 August 25	Argenica Receives IND Feedback From FDA × Argenica Receives IND Feedback From FDA
08 August 25	Bioshares Biotech Summit Presentation × Bioshares Biotech Summit Presentation
06 August 25	Argenica Appoints Vice President of Regulatory Affairs × Argenica Appoints Vice President of Regulatory Affairs
23 July 25	Quarterly Activities/Appendix 4C Cash Flow Report × Quarterly Activities/Appendix 4C Cash Flow Report
23 July 25	Ceasing to be a substantial holder from IFL × Ceasing to be a substantial holder from IFL
09 July 25	Application for quotation of securities - AGN × Application for quotation of securities - AGN
09 July 25	Notification of cessation of securities - AGN × Notification of cessation of securities - AGN
09 July 25	Application for quotation of securities - AGN × Application for quotation of securities - AGN
09 July 25	Cleansing Notice × Cleansing Notice
20 June 25	Argenica Awarded Federal Government Funding × Argenica Awarded Federal Government Funding
18 June 25	Argenica to Progress Clinical Development in TBI × Argenica to Progress Clinical Development in TBI
10 June 25	Update on Investigational New Drug Application × Update on Investigational New Drug Application
03 June 25	Notification regarding unquoted securities - AGN × Notification regarding unquoted securities - AGN
03 June 25	Notification of cessation of securities - AGN × Notification of cessation of securities - AGN
03 June 25	Change of Director's Interest Notice × Change of Director's Interest Notice
23 May 25	Investor Webinar × Investor Webinar
22 May 25	New US Patent for Surgical Stroke × New US Patent for Surgical Stroke
19 May 25	Investor Presentation × Investor Presentation
30 April 25	Quarterly Activities/Appendix 4C Cash Flow Report × Quarterly Activities/Appendix 4C Cash Flow Report
11 April 25	Last Patient Dosed in Phase 2 Stroke Trial × Last Patient Dosed in Phase 2 Stroke Trial
01 April 25	Notification of cessation of securities - AGN × Notification of cessation of securities - AGN
21 March 25	Change of Share Registry Details × Change of Share Registry Details

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

AGN Shortsell

Frequently Asked Questions

What is the current share price of Argenica Therapeutics Ltd (AGN:ASX)?

The current share price of Argenica Therapeutics Ltd (AGN:ASX) is AU$0.26.

What is the 52-week high share price for Argenica Therapeutics Ltd (AGN:ASX)?

The 52-week high share price for Argenica Therapeutics Ltd (AGN:ASX) is AU$0.88.

What is the 52-week low share price for Argenica Therapeutics Ltd (AGN:ASX)?

The 52-week low share price for Argenica Therapeutics Ltd (AGN:ASX)? is AU$0.60.

What is the dividend yield for Argenica Therapeutics Ltd (AGN:ASX)?

Argenica Therapeutics Ltd (AGN:ASX) does not pay a dividend.

What was Argenica Therapeutics Ltd (AGN:ASX) last dividend payment?

Argenica Therapeutics Ltd (AGN:ASX) does not pay a dividend.

What is the franking level for Argenica Therapeutics Ltd (AGN:ASX)?

Argenica Therapeutics Ltd (AGN:ASX) has a franking level of 0.0%.

In which sector is Argenica Therapeutics Ltd (AGN:ASX) classified?

Argenica Therapeutics Ltd (AGN:ASX) is classified in the Healthcare.

The current P/E ratio for Argenica Therapeutics Ltd (AGN:ASX) is .